Australia's Lumos Diagnostics on track for best day ever after FDA nod

Lumos Diagnostics Holdings

03/07/2023 03:10

** Shares of Lumos Diagnostics Holdings  LDX.AX  surge as
much as 445.5% to A$0.06 - set for best day ever, if gains hold
    ** LDX shares at its highest level since Sept 30, 2022
    ** Diagnostics solutions provider says it has received
clearance from the U.S. Food and Drug Administration (FDA) to
market its FebriDx test in U.S.
    ** Co says FebriDx is intended to be used in evaluating
patients for acute respiratory infection    
    ** Stock down ~77% YTD, as of last close
 

 (Reporting by Ayushman Ojha in Bengaluru)
 ((Ayushman.ojha@thomsonreuters.com;))